All of our hemp products provides CBDA, CBGA, CBD, CBC, CBG and CBL full spectrum extract, for maximum effect, and work much more effectively in the body than Isolate CBD and is Non-Psychoactive
Full spectrum extract help increase production of our own endocannabinoids by interacting in various ways with our endocannabinoid system (ECS). The primary receptor sites of the ECS are called CB1 and CB2. As a general rule, CB1 receptors are found mostly in our central nervous system and spinal cord, and CB2 receptors are mostly located in our organs and immune system.
Cannabidiolic acid (CBDA) is a particular strain of cannabis. It’s found unprocessed in the raw cannabis plant, but it isn’t a cannabinoid that’s easy to find on the market. CBDA is typically processed to become CBD. Like CBD, CBDA contains no more than 0.3% THC (the federal legal limit). It won’t get you high, but it has several medicinal benefits still being researched.
Cannabigerolic Acid (CBGA) is an essential cannabinoid; it’s the cannabinoid from which CBC, CBD, and THC are derived. CBGA has less than 0.3% THC, so it has no psychoactive effects. CBGA, similar to CBDA, has a few presumed medicinal benefits besides the ability to block SARS-CoV-2. Research has shown cardiovascular disease along with colon cancer cells respond to CBGA treatment. If you’re planning to shop for CBGA products, you might have a hard time. It’s not often found on its own but rather mixed with many other cannabinoids in CBD products.
Cannabidiol (CBD) is one of at least 60 active cannabinoids identified. It is a major Phyto cannabinoid, accounting for up to 40% of the plant’s extract. CBD is considered to have a wider scope of medical applications than tetrahydrocannabinol (THC). An orally-administered liquid containing CBD
research suggests that CBG may have some unique qualities that could prove to be particularly beneficial. And just like CBD, CBG is non-intoxicating, so it will not make you feel “high.”
It is not surprising to find out that CBG also contributes to easing everyday anxiety and stress. The findings of an animal study suggest CBG may help with everyday anxiety, stress, and muscle tension by modulating the effects of a brain chemical known as GABA.(3) This may be another example of CBG interacting with other body systems besides the ECS. The results of another animal behavior study showed signs that CBG may have potential to uplift mood.
Studies have showed several key interactions of CBC on gastrointestinal motility. CBC did alter mRNA expression of TRPA 1 receptors ex vivo but did not change endocannabinoid levels. CBC normalized inflammation and the croton-oil induced hypermotility in vivo, suggesting that CBC may reduce hypermobility independently of the compounds ability to bind with cannabinoid receptors or TRPA1 receptors.
CBC shows potential in anti-inflammatory properties through its ability to bind with transient receptor potential channels of both the vanilloid type-1 (TRPV1) receptor and ankyrin type-1 receptor (TRPA1). These receptors are linked to pain perception and upon activation increase endocannabinoids within the body to assist in anti-inflammatory response.  CBC has also been shown to act on pain in a different manner than common non-steroidal anti-inflammatory drugs while exhibiting none of the side effects of these over the counter medications.
A number of small studies of smoked marijuana found that it can be helpful in treating nausea and vomiting from cancer chemotherapy.
A few studies have found that inhaled (smoked or vaporized) marijuana can be helpful treatment of neuropathic pain (pain caused by damaged nerves).
Smoked marijuana has also helped improve food intake in HIV patients in studies.
Studies have long shown that people who took marijuana extracts in clinical trials tended to need less pain medicine.
More recently, scientists reported that THC and other cannabinoids such as CBD slow growth and/or cause death in certain types of cancer cells growing in lab dishes. Some animal studies also suggest certain cannabinoids may slow growth and reduce spread of some forms of cancer.
There have been some early clinical trials of cannabinoids in treating cancer in humans and more studies are planned. While the studies so far have shown that cannabinoids can be safe in treating cancer, they do not show that they help control or cure the disease.
Relying on marijuana alone as treatment while avoiding or delaying conventional medical care for cancer may have serious health consequences.
TEL AVIV, Israel and BETHESDA, Maryland, Jan. 27, 2020 /PRNewswire/PRESS RELEASE -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a series of tests conducted at the company's High Through-put Screening (HTS) facility in Israel, it has been shown that the cannabinoids CBC (cannabichromene) and CBG (cannabigerol) both exhibit anti-tumor properties, tested on human gastrointestinal cancer cells.
CBC is an additional non-intoxicating cannabinoid and is one of the naturally occurring phytocannabinoids. It bears a host of potential positive therapeutic qualities and may promote antimicrobial, anti‐inflammatory, analgesic, and neurogenesis activity. It is particularly found in younger cannabis plants, albeit in small quantities.
In these tests, the HTS platform was utilized to screen the necrotic effects of a variety of cannabinoids on human gastrointestinal cancer cells, in addition to other cancer types previously tested. CBC and CBG were both shown to induce significantly higher rates of necrosis in these cancer cells compared to other cannabinoids, thus strengthening previously obtained results.
Nabiximols (USAN, trade name Sativex) is an aerosolized mist for oral administration containing a near 1:1 ratio of CBD and THC. The drug was approved by Canadian authorities in 2005 to alleviate pain associated with multiple sclerosis.
In October 2003, U.S. patent #6630507 entitled “Cannabinoids as antioxidants and neuroprotectants” was assigned to “The United States Of America As Represented By The Department Of Health And Human Services.” The patent was filed in April 1999 and listed as the inventors: Aidan J. Hampson, Julius Axelrod, and Maurizio Grimaldi, who all held positions at the National Institute of Mental Health (NIMH) in Bethesda, MD, which is part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). The patent mentions cannabidiol’s ability as an antiepileptic, to lower intraocular pressure in the treatment of glaucoma, lack of toxicity or serious side effects in large acute doses, its neuroprotectant properties, its ability to prevent neurotoxicity mediated by NMDA, AMPA, or kainate receptors; its ability to attenuate glutamate toxicity, its ability to protect against cellular damage, its ability to protect brains from ischemic damage, its anxiolytic effect, and its superior antioxidant activity which can be used in the prophylaxis and treatment of oxidation associated diseases.
“Oxidative associated diseases include, without limitation, free radical associated diseases, such as ischemia, ischemic reperfusion injury, inflammatory diseases, systemic lupus erythematous, myocardial ischemia or infarction, cerebrovascular accidents (such as a thromboembolic or hemorrhagic stroke) that can lead to ischemia or an infarct in the brain, operative ischemia, traumatic hemorrhage (for example a hypovolemic stroke that can lead to CNS hypoxia or anoxia), spinal cord trauma, Down’s syndrome, Crohn’s disease, autoimmune diseases (e.g. rheumatoid arthritis or diabetes), cataract formation, uveitis, emphysema, gastric ulcers, oxygen toxicity, neoplasia, undesired cellular apoptosis, radiation sickness, and others. The present invention is believed to be particularly beneficial in the treatment of oxidative associated diseases of the CNS, because of the ability of the cannabinoids to cross the blood brain barrier and exert their antioxidant effects in the brain. In particular embodiments, the pharmaceutical composition of the present invention is used for preventing, arresting, or treating neurological damage in Parkinson’s disease, Alzheimer’s disease and HIV dementia; autoimmune neurodegeneration of the type that can occur in encephalitis, and hypoxic or anoxic neuronal damage that can result from apnea, respiratory arrest or cardiac arrest, and anoxia caused by drowning, brain surgery or trauma (such as concussion or spinal cord shock).”
We follow only the best industry standards, making our Hemp Products the most effective and the highest quality Organic California Hemp on the market today. It is legal in all 50 states and is hand crafted for you then batch tested using third part labs for potency true to fact data product assurance. As a company we are focused on the welfare of our customers giving the best products.